Rodríguez-Medina B, Blanes M, Vinaixa C, Aguilera V, Rubín Á, Prieto M, Berenguer M

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 974-978
Archivo PDF: 86.77 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rouphael NG, Talati NJ, Vaughan C, et al. Infections associated with haemophagocytic syndrome. The Lancet infectious diseases 2007; 7: 814-22.

2. Brastianos PK, Swanson JW, Torbenson M, et al: Tuberculosis- associated haemophagocytic syndrome. The Lancet infectious diseases 2006; 6: 447-54.

3. Wong CK, Wong BC, Chan KC, et al. Cytokine profile in fatal human immunodeficiency virus tuberculosis Epstein- Barr virus associated hemophagocytic syndrome. Archives of internal medicine 2007; 167: 1901-3.

4. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Annals of Medicine 2006; 38: 20-31.

5. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.

6. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatology 2012; 56: 455-63.

7. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 151-6.

8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

9. Lin KH, Hsu PI, Yu HC, et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterology 2012; 12: 7.

10. Gelb AM, Brazenas N, Sussman H, et al. Acute granulomatous disease of the liver. American Journal of Digestive diseases 1970; 15: 842-7.

11. Gibson JA. Granulomatous liver disease and portal hypertension. Proceedings of the Royal Society of Medicine 1973; 66: 502-3.

12. Flamm SL. Granulomatous liver disease. Clinics in liver disease 2012; 16: 387-96.

13. Vakiani E, Hunt KK, Mazziotta RM, et al. Hepatitis C-associated granulomas after liver transplantation: morphologic spectrum and clinical implications. Am J Clin Pathol 2007; 127: 128-34.

14. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005; 141: 865-8.

15. Aggarwal P, Kumar G, Dev N, et al. Haemophagocytic lymphohistiocytosis: a cause for rare but fatal outcome in tuberculosis. BMJ case reports 2012; 2012.

16. Numakura T, Matsuura Y, Takiguchi H, et al. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi 2010; 48: 449-53.

17. Baraldes MA, Domingo P, Gonzalez MJ, et al. Tuberculosisassociated hemophagocytic syndrome in patients with acquired immunodeficiency syndrome. Arch Intern Med 1998; 158: 194-5.

18. Ruiz-Arguelles GJ, Arizpe-Bravo D, Garces-Eisele J, et al. Tuberculosis-associated fatal hemophagocytic syndrome in a patient with lymphoma treated with fludarabine. Leukemia & lymphoma 1998; 28: 599-602.

19. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-9, e1131.

20. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-17.